IceCure Medical Ltd - Special Call Company Participants Eyal Shamir - CEO & Director Shad Good Ronen Tsimerman - CFO & COO Conference Call Participants Michael Polyviou - EVC Group Inc. Anthony Vendetti - Maxim Group LLC, Research Division Brian Kemp Dolliver - Brookline Capital Markets, LLC, Research Division Presentation Operator Good morning, and thank you for standing by. [Operator Instructions] Please be advised that today's conference call is being recorded.
IceCure Medical shares surge after FDA clears ProSense, marking the first minimally invasive breast cancer treatment for women aged 70 and above.
IceCure Medical Ltd (NASDAQ:ICCM ) Q2 2025 Earnings Conference Call August 13, 2025 10:00 AM ET Company Participants Michael Polyviou - IR, EVC Group Inc. Eyal Shamir - CEO & Director Ronen Tsimerman - CFO & COO Conference Call Participants Brian Kemp Dolliver - Brookline Capital Markets, LLC, Research Division Anthony V. Vendetti - Maxim Group LLC, Research Division Eduardo Rafael Martinez-Montes - H.C.
IceCure Medical Ltd. (ICCM) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.06 per share.
IceCure Medical Ltd (NASDAQ:ICCM ) Q1 2025 Earnings Conference Call May 28, 2025 10:00 AM ET Company Participants Michael Polyviou - IR Eyal Shamir - CEO Ronen Tsimerman - CFO and COO Conference Call Participants Anthony Vendetti - Maxim Group Kemp Dolliver - Brookline Capital Markets Operator Good morning, and thank you for standing by. Currently, all the participants are in a listen-only mode.
ICCM reports strong kidney cancer cryoablation study results, showcasing 88.7% recurrence-free rates and reinforcing its position in cryoablation technology.
IceCure Medical Ltd (NASDAQ:ICCM ) Q4 2024 Earnings Conference Call March 27, 2025 10:00 AM ET Company Participants Michael Polyviou - Investor Relations Eyal Shamir - Chief Executive Officer and Director Ronen Tsimerman - Chief Financial Officer and Chief Operating Officer Conference Call Participants Kemp Dolliver - Brookline Capital Markets Anthony Vendetti - Maxim Group Operator Good morning, and thank you for standing by. Currently, all the participants' are in a listen-only mode.
IceCure Medical Ltd (NASDAQ:ICCM ) Q3 2024 Earnings Conference Call November 26, 2024 10:00 AM ET Company Participants Michael Polyviou - IR Ronen Tsimerman - CFO and Chief Operating Officer Tlalit Tel-Tzure - VP of Business Development and Global Marketing Shay Levav - VP of Regulatory and Quality Affairs and Clinical Applications Conference Call Participants Anthony Vendetti - Maxim Group Kemp Dolliver - Brookline Capital Markets Yi Chen - H.C. Wainwright Operator Good morning, and thank you for standing by.
IceCure Medical Ltd. (ICCM) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07.
IceCure Medical Ltd. (ICCM) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.07.
IceCure Medical Ltd. ICCM recently announced the publication of data from an independent study evaluating its ProSense cryoablation system in the peer-reviewed journal — Cancers.
IceCure Medical Ltd ICCM recently announced that it has received marketing authorization from the FDA for its next-generation single probe cryoablation system, XSense Cryoablation System with CryoProbes.